Opinion|Videos|January 15, 2025
Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs
Author(s)Thomas J. Herzog, MD, John Chan, MD
Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr Chan to Dr Herzog: What adverse events are most seen with PARPi therapy, and how do you mitigate or manage these?
- Dr Herzog: Briefly comment on recent data surrounding ADCs in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
- Dr Herzog to address: Mirvetuximab soravtansine (anti-FR)
- FORWARD II (
Gynecol Oncol. 2024 MIRASOL) (N Engl J Med. 2023 ;ASCO 2024 abstract 5582 ) - Dr Chan to address: Luveltamab tazevibulin (anti-FR), Rinatabart sesutecan (Rina-S)
- Rinatabart sesutecan (Rina-S) -
Lee EK, et al. ESMO 2024. Abs 719MO - STRO-002-GM1 (
Pothuri, et al. ESMO 2023. Abstract 741MO )
- All faculty: Please share future perspectives and closing thoughts on the treatment of ovarian cancer.
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring
5